Skip to main content
. Author manuscript; available in PMC: 2009 Jun 30.
Published in final edited form as: Clin Trials. 2008;5(2):157–167. doi: 10.1177/1740774508089459

Figure 1.

Figure 1

Estimating the relative efficacy of didanosine (ddI) and zalcitabine (ddC) in patients with HIV. Estimates (*) and confidence intervals (CIs) for the relative risks for progression-free survival, by the date of interim analysis. Appearing on the left is the date of the interim analysis and the number of events on ddI and ddC arms at that time. Square brackets are 95% CIs; curly brackets are proper group sequential repeated CIs